BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30358851)

  • 1. Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region.
    Lopez B; Siqueira de Oliveira R; Pinhata JMW; Chimara E; Pacheco Ascencio E; Puyén Guerra ZM; Wainmayer I; Simboli N; Del Granado M; Palomino JC; Ritacco V; Martin A
    J Antimicrob Chemother; 2019 Feb; 74(2):373-379. PubMed ID: 30358851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
    Zimenkov DV; Nosova EY; Kulagina EV; Antonova OV; Arslanbaeva LR; Isakova AI; Krylova LY; Peretokina IV; Makarova MV; Safonova SG; Borisov SE; Gryadunov DA
    J Antimicrob Chemother; 2017 Jul; 72(7):1901-1906. PubMed ID: 28387862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.
    Torrea G; Coeck N; Desmaretz C; Van De Parre T; Van Poucke T; Lounis N; de Jong BC; Rigouts L
    J Antimicrob Chemother; 2015 Aug; 70(8):2300-5. PubMed ID: 25977401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants.
    Ismail N; Omar SV; Ismail NA; Peters RPH
    J Microbiol Methods; 2018 Oct; 153():1-9. PubMed ID: 30165087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
    Kaniga K; Hasan R; Jou R; Vasiliauskienė E; Chuchottaworn C; Ismail N; Metchock B; Miliauskas S; Viet Nhung N; Rodrigues C; Shin S; Simsek H; Smithtikarn S; Ngoc ALT; Boonyasopun J; Kazi M; Kim S; Kamolwat P; Musteikiene G; Sacopon CA; Tahseen S; Vasiliauskaitė L; Wu MH; Vally Omar S
    J Clin Microbiol; 2022 Jan; 60(1):e0291920. PubMed ID: 34705538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
    Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an
    de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
    Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
    J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
    Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
    Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with Mycobacterium tuberculosis Lineage.
    Rivière E; Verboven L; Dippenaar A; Goossens S; De Vos E; Streicher E; Cuypers B; Laukens K; Ben-Rached F; Rodwell TC; Pain A; Warren RM; Heupink TH; Van Rie A
    Antimicrob Agents Chemother; 2022 Jul; 66(7):e0032222. PubMed ID: 35758754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
    Rancoita PMV; Cugnata F; Gibertoni Cruz AL; Borroni E; Hoosdally SJ; Walker TM; Grazian C; Davies TJ; Peto TEA; Crook DW; Fowler PW; Cirillo DM;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.
    Kaniga K; Cirillo DM; Hoffner S; Ismail NA; Kaur D; Lounis N; Metchock B; Pfyffer GE; Venter A
    J Clin Microbiol; 2016 Dec; 54(12):2956-2962. PubMed ID: 27654337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
    Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis using the fast resazurin microtiter assay plate.
    Pina RZ; Caleffi-Ferracioli KR; Campanerut-Sá PA; Ghiraldi-Lopez LD; Pavan FR; Siqueira VL; Scodro RB; Cardoso RF
    Int J Tuberc Lung Dis; 2016 Nov; 20(11):1535-1538. PubMed ID: 27776597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the broth microdilution plate methodology for susceptibility testing of Mycobacterium tuberculosis in Peru.
    Puyén ZM; Santos-Lázaro D; Vigo AN; Coronel J; Alarcón MJ; Cotrina VV; Moore DAJ
    BMC Infect Dis; 2022 Aug; 22(1):705. PubMed ID: 36002805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis.
    Gupta S; Cohen KA; Winglee K; Maiga M; Diarra B; Bishai WR
    Antimicrob Agents Chemother; 2014; 58(1):574-6. PubMed ID: 24126586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.